Türköz A, Ciğli A, But K, Sezgin N, Türköz R, Gülcan O, Ersoy M O
Department of Anesthesiology, Inönü University Hospital, Malatya, Turkey.
J Cardiothorac Vasc Anesth. 2001 Oct;15(5):603-10. doi: 10.1053/jcan.2001.26539.
To compare the efficacy of aprotinin and methylprednisolone in reducing cardiopulmonary bypass (CPB)-induced cytokine release, to evaluate the effect of myocardial cytokine release on systemic cytokine levels, and to determine the influence of cytokine release on perioperative and postoperative hemodynamics.
Prospective, randomized clinical trial.
University teaching hospital and clinics.
Thirty patients undergoing elective coronary artery bypass graft surgery.
Patients were randomly allocated into groups treated with aprotinin (n = 10) or methylprednisolone (n = 10) or into an untreated control group (n = 10). Aprotinin-treated patients received aprotinin as a high-dose regimen (6 x 10(6) KIU), and methylprednisolone-treated patients received methylprednisolone (30 mg/kg intravenously) before CPB.
Patients were analyzed for hemodynamic changes and alveolar-arterial PO2 difference (AaDO2) until the first postoperative day. Plasma levels of proinflammatory cytokines (tumor necrosis factor [TNF]-alpha, interleukin [IL]-1beta, IL-6, and IL-8) were measured in peripheral arterial blood immediately before the induction of anesthesia, 5 minutes before CPB, 3 minutes after the start of CPB, 2 minutes after the release of the aortic cross-clamp, 1 hour after CPB, 6 hours after CPB, and 24 hours after CPB; and in coronary sinus blood immediately before CPB and 2 minutes after the release of the aortic cross-clamp. The hemodynamic parameters did not differ among the groups throughout the study. After CPB, AaDO2 significantly increased (p < 0.05) in all groups. A significant decrease in AaDO2 was observed in aprotinin-treated patients at 24 hours after CPB compared with the other groups (p < 0.05). TNF-alpha level from peripheral arterial blood significantly increased in control patients 1 hour after CPB (p < 0.01) and did not significantly increase in methylprednisolone-treated patients throughout the study. In all groups, IL-6 levels increased after the release of the aortic cross-clamp and reached peak values 6 hours after CPB. At 6 hours after CPB, the increase in IL-6 levels in methylprednisolone-treated patients was significantly less compared with levels measured in control patients and aprotinin-treated patients (p < 0.001). In control patients, IL-8 levels significantly increased 2 minutes after the release of the aortic cross-clamp (p < 0.05), and peak values were observed 1 hour after CPB (p < 0.01). IL-8 levels in control patients were significantly higher compared with patients treated with aprotinin and patients treated with methylprednisolone 1 hour after CPB (p < 0.05).
This study showed that methylprednisolone suppresses TNF-alpha, IL-6, and IL-8 release; however, aprotinin attenuates IL-8 release alone. Methylprednisolone does not produce any additional positive hemodynamic and pulmonary effects. An improved postoperative AaDO2 was observed with the use of aprotinin.
比较抑肽酶和甲泼尼龙在减少体外循环(CPB)诱导的细胞因子释放方面的疗效,评估心肌细胞因子释放对全身细胞因子水平的影响,并确定细胞因子释放在围手术期和术后血流动力学方面的影响。
前瞻性随机临床试验。
大学教学医院及诊所。
30例行择期冠状动脉旁路移植术的患者。
患者被随机分为接受抑肽酶治疗组(n = 10)、甲泼尼龙治疗组(n = 10)或未治疗的对照组(n = 10)。接受抑肽酶治疗的患者接受高剂量方案的抑肽酶(6×10⁶KIU),接受甲泼尼龙治疗的患者在CPB前静脉注射甲泼尼龙(30mg/kg)。
对患者进行血流动力学变化及肺泡 - 动脉血氧分压差(AaDO₂)分析,直至术后第一天。在麻醉诱导前即刻、CPB前5分钟、CPB开始后3分钟、主动脉阻断钳松开后2分钟、CPB后1小时、CPB后6小时以及CPB后24小时,测定外周动脉血中促炎细胞因子(肿瘤坏死因子[TNF]-α、白细胞介素[IL]-1β、IL-6和IL-8)的血浆水平;并在CPB前即刻和主动脉阻断钳松开后2分钟测定冠状窦血中上述细胞因子水平。在整个研究过程中,各组血流动力学参数无差异。CPB后,所有组的AaDO₂均显著升高(p < 0.05)。与其他组相比,CPB后24小时,接受抑肽酶治疗的患者AaDO₂显著降低(p < 0.05)。CPB后1小时,对照组外周动脉血中TNF-α水平显著升高(p < 0.01),而在整个研究过程中甲泼尼龙治疗组患者该水平未显著升高。在所有组中,主动脉阻断钳松开后IL-6水平升高,并在CPB后6小时达到峰值。CPB后6小时,甲泼尼龙治疗组患者IL-6水平的升高幅度显著低于对照组和抑肽酶治疗组患者(p < 0.001)。在对照组患者中,主动脉阻断钳松开后2分钟IL-8水平显著升高(p < 0.05),并在CPB后1小时达到峰值(p < 0.01)。CPB后1小时,对照组患者的IL-8水平显著高于接受抑肽酶治疗的患者和接受甲泼尼龙治疗的患者(p < 0.05)。
本研究表明,甲泼尼龙可抑制TNF-α、IL-6和IL-8的释放;然而,抑肽酶仅能减弱IL-8的释放。甲泼尼龙未产生任何额外的积极血流动力学和肺部效应。使用抑肽酶可使术后AaDO₂得到改善。